carboplatin,durvalumab,gemcitabine,paclitaxel,vinorelbine,cisplatin,nivolumab,docetaxel,pemetrexed,ipilimumab,pembrolizumab
astrazeneca,merck,bms
['keynote671', 'keynote,671', 'aegean', 'cm816', 'lcsm,(-blcsm)', 'key,note,42']
#keynote671 presented at #asco23 by dr. mark awad #lcsm efs, trend toward os benefit of this neoadj/adj chemo/io strategy vs neoadj chemo alone is impressive- pcr rates of 18% vs 4% hr 0.42 pdl1&gt;50%, hr 0.51 1-49% and hr0.77 in pdl1 neg (&gt;0.5)
#cm816 + #aegean 
Fellowship Program Director 👨‍🏫 Hematology & Oncology at George Washington University. Thoracic and Head&Neck cancer.